Stockholm, January 28, 2022 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the initial patient enrollments in the ACTIVE (Use of Active Fluid Exchange to Treat Intraventricular Hemorrhage (IVH)) clinical study. The objective of the ACTIVE study is to evaluate the efficacy and safety of the IRRAflow system’s active irrigation and drainage compared to passive external ventricular drainage (EVD) alone. 

The ACTIVE study is a randomized, prospective clinical trial that consists of two arms. The first arm will assess the treatment of 60 IVH patients using IRRAflow and will compare the results to a second arm of 58 patients that will be treated with traditional passive EVDs. The study will compare overall effectiveness of the two treatment arms by looking at overall blood clearance, treatment time required, and long-term patient outcomes. Additionally, the safety of each treatment arm will be compared by assessing treatment complications, including catheter occlusions and infection. The clinical trial has also been designed for endpoint comparisons to be conducted at multiple interim checkpoints throughout enrollment.

“We are pleased to enroll our first patient in the ACTIVE study,” said Dr. Anders Korshøj. “We believe that the use of active irrigation may enhance outcomes for IVH patients, and we look forward to presenting our data from ACTIVE to confirm that IRRAflow’s unique mechanism of action reduces complications and treatment times.”

The Department of Neurosurgery at Aarhus University Hospital is one of the leading neurosurgical departments in Denmark. The department is responsible for general neurosurgery and highly specialized neurosurgical procedures in the central Denmark Region. Moreover, the department is responsible for diagnostics, treatment, and care of patients with certain neurosurgical conditions in the entire country.

“The first patient enrollment of the ACTIVE study is a critical step forward for our company,” said Will Martin, President and CEO of IRRAS. “The most important step to accelerate the commercial adoption of IRRAflow is to confirm its superiority to traditional drainage, and the ACTIVE trial will provide comparative data that demonstrates how IRRAflow is a better choice for patients suffering from IVH.”

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

About Aarhus University and Aarhus University Hospital

Aarhus University Hospital belongs to the elite of university hospitals. Aarhus University Hospital develops and provides highly specialized medical treatment, research, and education at an international level. Aarhus University Hospital serves the citizens from across the Central Denmark Region in need of highly specialized treatment. For the last 13 years, Aarhus University Hospital has been appointed Denmark’s best hospital, and it currently ranks #32 on the Newsweek ranking of the world’s best hospitals.

Aarhus University (AU) is a dynamic, modern and highly international university. Since its founding in 1928, it has grown to become a leading public university with international impact and reach across the entire research spectrum. Out of over 17,000 universities worldwide, AU ranks among the top 100 universities in the world in several research areas and is considered among the top 25 universities in the European Union. AU stands out in particular in terms of research quality and the quality of degree programs. Regarding internationalization, AU is ranked in the top as well as no. 45 on THE’s ranking “Most International Universities in the World”.

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on January 28, 2022, at 8:30 (CET).

Stockholm, January 12, 2022 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the issuance of United States (U.S.) Patent Number 11,123,483, “Fluid Exchange Catheter System.”  This latest patent is the third US patent that provides intellectual property protection for the company’s lead product, IRRAflow, and it provides expanded coverage regarding the system’s ability to facilitate the targeted delivery of therapeutic medication into targeted areas of treatment.

The recently issued patent includes two key method claims regarding the IRRAflow system’s active fluid exchange mechanism of action.  The patent’s protection covers:

1. The administration of at least one drug to a patient through the catheter; and
2. The irrigation mechanism for unblocking the fluid exchange pores at the distal end of the catheter. 

The issuance of the latest patent adds to the existing intellectual property protection for the IRRAflow system and builds upon the previously issued US patents, U.S. Patent No. 8,398,581, issued on March 19, 2013, and U.S. Patent No. 9,623,177, issued on April 18, 2017.  IRRAS’ IRRAflow and Hummingbird ICP Monitoring product families now contain 12 total patents nationalized globally across 13 key countries.

“Strengthening our intellectual property portfolio with the addition of this patent further confirms the innovative technology contained with the IRRAflow system,” said Will Martin, President and Chief Executive Officer of IRRAS.  “Over the past year, global thought leaders in neurosurgery from Helsinki University Hospital and Buffalo General Medical Center centers have published cutting-edge clinical experience using IRRAflow to deliver both thrombolytic and antibiotic medication.  Moving forward, IRRAS is committed to capitalizing upon this sizable opportunity in intracranial drug delivery, and this patent is an important foundational element of our company’s long-term growth plans.”

IRRAflow, the company's initial commercial product, is a transformative medical device system that combines controlled irrigation with ongoing fluid drainage to better manage patients with intracranial bleedings.  The system's automated use of irrigation addresses challenges associated with traditional passive fluid drainage, such as catheter blockages and infection. In addition, IRRAflow's irrigating fluid helps to dilute toxic material, such as blood or bacteria, that is collected within the intracranial space and makes it easier to remove.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on January 12, 2022, at 8:30 (CET).

Stockholm, December 23, 2021 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that it has entered into a non-exclusive distribution agreement with Lovell Government Services, a Service-Disabled Veteran-Owned Small Business (“SDVOSB”), to serve as the company’s vendor for product orders and contract awards from United States government facilities.  This partnership will help IRRAS accelerate the launch of its IRRAflow and Hummingbird ICP product lines by utilizing Lovell’s position as a contracted vendor at Veterans Affairs (VA) hospitals and other United States government and military medical facilities.

“The IRRAS commercial team is excited to partner with the Lovell Government Services team as their deep experience and established contracts with VA and military medical facilities will provide guidance and strategic advantages as we expand within this important group of customers,” said Will Martin, President and CEO of IRRAS. “Our IRRAS team is dedicated to offering innovative, life-saving technology for all patients, but it is especially meaningful that this partnership will allow us to positively impact the lives of more patients that have volunteered to serve their country.”

Lovell, a Service-Disabled Veteran-Owned Small Business, is ranked as 2021’s fastest-growing privately held company in Government Services by Inc. 5000. They partner with medical and pharmaceutical companies looking to serve veteran and military patient populations and to compete for government contracts. With this partnership, Federal, State, and Local Government Agencies will be able to place orders for the IRRAflow or Hummingbird ICP product lines through appropriate contract vehicles, such as the Defense Logistics Agency’s ECAT system, the Federal Supply Schedule (FSS), the Distribution and Pricing Agreement (DAPA), and GSA Advantage for direct purchase.  Partnering with an SDVOSB also benefits government agencies by helping them meet their SDVOSB procurement goals and requirements.

“IRRAS has developed innovative devices dedicated to treating intracranial bleeding and traumatic brain injury, which unfortunately affect the communities that we serve in a disproportionate manner. The IRRAflow and Hummingbird devices will save and improve the lives of thousands of Veterans, active-duty service members, and their dependents. We’re honored that IRRAS is partnering with us,” says Chris Lovell, Major, USMC (Ret.), and CEO of Lovell Government Services.

About Lovell Government Services

Lovell Government Services was established by Chris Lovell, Major USMC Retired, in 2013. Lovell’s mission is to serve the Veterans Administration Hospital System, the U.S. Military Medical Networks, other Federal Healthcare Systems, and the communities they support. Lovell partners with Medical and Pharmaceutical Suppliers to fast track and distribute the latest in life-saving technologies to the Federal Government. Learn more at www.lovellgov.com

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on December 23, 2021, at 8:30 (CET).

Stockholm, December 3, 2021 – According to the principles for the appointment of the Nomination Committee in IRRAS AB (publ), the Nomination Committee for the annual general meeting 2022 shall be composed of members that represent the three largest shareholders after the end of the third quarter of the year before the AGM is held, together with the chairman of the company’s Board of Directors. The largest shareholders refer to the registered shareholders or otherwise known shareholders after the end of the third quarter.

The composition of the Nomination Committee has now been established, and IRRAS today announced that the Nomination Committee for the annual general meeting 2022 consists of the following persons:

• Christer Hellström, chairman of the nomination committee, representing Bacara Holdings Limited
• Arne Lööw, representing Fourth National Pension Fund
• Carl-Mikael Lindholm, representing Carl-Olof och Jenz Hamrins Stiftelse
• Marios Fotiadis, Chairman of the Board of IRRAS AB

The Nomination Committee’s proposals will be presented in the Notice to the annual general meeting 2022 and on IRRAS’ website, www.irras.com.

Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to nomination@irras.com (subject “Nomination Committee”) or by letter posted to IRRAS AB, Attn: IRRAS Nomination Committee, Vasagatan 16, 111 20 Stockholm, Sweden.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on December 3, 2021 at 8:30 (CET).

Fifth Consecutive Quarter of Revenue Growth

“Q3 marked our company’s 5th consecutive quarter of growth, even with increased impact during the quarter from the COVID-19 Delta variant. This growth and the strengthening foundation of our business show that IRRAS is well positioned to continue this positive growth trajectory.”

“We are pleased with our accomplishments during the third quarter of 2021, and our continued progress across the key elements of our business – revenue growth, operational efficiency, and clinical data generation – confirms our forward momentum.”

Will Martin, President and CEO of IRRAS

Third Quarter, July – September 2021, Results

• Net revenue amounted to SEK 6.1 million (2.1)
• Operating loss (EBIT) amounted to SEK -27.0 million (-31.0)
• Loss after tax amounted to SEK -26.9 million (-31.0)
• Earnings per share before and after dilution amounted to SEK -0.34 (-0.47)

Period, January – September 2021, Results

• Net revenue amounted to SEK 15.2 million (4.9)
• Operating loss (EBIT) amounted to SEK -93.0 million (-97.5)
• Loss after tax amounted to SEK -92.9 million (-97.8)
• Earnings per share before and after dilution amounted to SEK -1.30 (-1.90)

Important events during the quarter

Company Leadership Transition Completed

• On July 1, Will Martin assumed the role of IRRAS President & Chief Executive Officer.  Kleanthis G. Xanthopoulos, Ph.D. remains on the company’s Board of Directors.

Loan Financing Completed via European Investment Bank

• IRRAS signed a 10M EUR loan agreement that provides non-dilutive financing for IRRAS to fund product development and clinical data generation activities being performed in the EU.

Ventriculitis Case Study Published

• Helsinki University Hospital published a case series that confirmed the ability of IRRAflow to treat patients with pyogenic ventriculitis, an aggressive brain infection.
• Publication documents the ability of IRRAflow to directly deliver antibiotics into the intracranial space for the first time in peer-reviewed literature.

Expanded Quality System Certifications Received after Onsite Inspection

• IRRAS’ in-house manufacturing facility for IRRAflow capital equipment was added to its ISO 13485:2016 certification, and the company’s MDSAP certificate was extended for 3 years.

Important events after the end of the quarter

CE Mark certification received for enhanced IRRAflow Drainage Catheter

• Enhanced catheter with improved kink resistance and increased drainage capabilities now available for patient treatments in Europe.

ACTIVE clinical study initiated by Aarhus University Hospital

• Aarhus University Hospital, a leading hospital in Denmark, began commercial patient treatments with IRRAflow and will capture its results in the ACTIVE investigator-initiated clinical trial to prove the system’s superiority versus traditional drainage systems.

First patients enrolled in ARCH clinical study

• Dr. Behnam Rezai Jahromi from Helsinki University Hospital enrolled the first patients in the ARCH clinical study, which compares use of IRRAflow with clot-busting medication versus traditional drainage systems in patients with intraventricular hemorrhage.

The report is available on the company’s website:  https://investors.irras.com/en/reports-presentations.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

USA
Will Martin
President and CEO
ir@irras.com

Europe

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

This document is considered information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on November 9, 2021 at 8:00 a.m. (CET).

 IRRAS AB (publ) interim report for January to September 2021

Stockholm, November 4, 2021 – On Tuesday, November 9, at 09.00 CET, IRRAS will host a conference call and an online presentation of its Q3 2021 interim report (which will have been published earlier on November 9 at 08.00 CET). The presentation will be held in English.

The dial-in numbers for the conference call are:
Sweden: +46 8 50 55 83 59
Rest of the world: +44 33 33 00 92 71

The presentation will be webcast and can be accessed from the following web address:

https://tv.streamfabriken.com/irras-q3-2021

Speakers: President and CEO Will Martin, Interim CFO Griffen Stapp, and Head of Investor Relations Sten Gustafsson

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on November 4, 2021 at 8:00 (CET).

Stockholm, October 28, 2021 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the initial patient enrollment in the ARCH (Active Removal of IntraCerebral Hematoma via active irrigation of ventricular system) clinical trial. The ARCH study will compare the ability of the company’s IRRAflow system to clear the blood collected in a patient’s ventricles after an intraventricular hemorrhage (IVH) more effectively than traditional passive drainage.  The ARCH investigators hypothesize that IRRAflow’s active irrigation, when combined with thrombolytic medication, will reduce the time needed to clear blood from the intraventricular space, thereby improving patient outcomes. 

The ARCH study is a controlled, randomized clinical trial that is expected to enroll 60 patients across a number of sites in both Europe and the United States.  The team at Helsinki University Hospital, led by neurosurgeon Dr. Behnam Rezai Jahromi and Dr. Jari Siironen, Head of Neurosurgical ICU, will lead the international collection of leading neurosurgical centers that will participate in the study.

"We are extremely excited to start and lead the international ARCH clinical study and confirm that using irrigation to deliver medication can actively change the composition of cerebrospinal fluid (CSF) and improve the poor prognosis of patients with IVH,” said Dr. Rezai Jahromi. “Our encouraging preliminary data was recently presented at the Congress of Neurological Surgeons (CNS) 2021 annual meeting, and we believe that the ARCH study can build upon these results and have a tremendous impact on IVH treatment decisions.”

The study’s three-arm design will compare IRRAflow versus traditional ventricular drainage when treating IVH in conjunction with tissue plasminogen activator (tPA), a medication used in stroke to dissolve clot.

• Arm 1 – Use of standard, passive EVD with manual bolus introduction of tPA according to the protocol outlined in the previously published CLEAR trial series.  
• Arm 2 – Use of IRRAflow system with manual bolus introduction of tPA according to the CLEAR protocol, followed by IRRAflow’s active irrigation.  
• Arm 3 – Use of IRRAflow system with continuous infusion of tPA via IRRAflow’s active irrigation mechanism of action.  

Additional sites are expected to be added to the ARCH study in coming months, and patient enrollment is expected to continue throughout 2022.  The trial has been designed for interim results to be announced at various intervals during patient enrollment.

“The initiation of the ARCH study is pivotal inflection point in the growth of IRRAS,” said Will Martin, President and CEO of IRRAS. “Early adopters of the system believe IRRAflow is a transformational step forward in improving IVH outcomes, and, now, our company is investing in the comparative data that will serve as a critical next step toward making IRRAflow a standard of care.”

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS). 

For more information, please contact:

USA
Will Martin
President and CEO
ir@irras.com 

Europe
Sten Gustafsson
Director, Investor Relations
ir@irras.com

The information was released for public disclosure, through the agency of the contact person above, on October 28, 2021 at 08:30 (CET). 

Stockholm, October 22, 2021 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the initial project from its previously announced collaboration with Aarhus University Hospital in Aarhus, Denmark, one of the world’s leading medical institutions. In conjunction with the Aarhus University’s Technology Transfer Office (TTO) and Department of Electrical and Computer Engineering (ECE), and neurosurgeon Dr. Anders Korshøj, IRRAS will work to develop brain compliance monitoring software that resides on its flagship product, IRRAflow. When combined with IRRAflow’s active treatment, such software would improve decision-making by providing physicians real-time information regarding the effectiveness and completion of treatment.

“Our mission at IRRAS is to develop innovative technologies that fundamentally change how neurocritical care patients are treated, and being able to measure brain compliance in real-time is a perfect example,” said Will Martin, President and CEO of IRRAS.  “Partnering with leading experts in this field to advance their patient treatment with IRRAflow and collaboratively develop groundbreaking technology is critical to our long-term success.”

Intracranial compliance expresses the capability of a patient’s brain to withstand an increase in intracranial volume without experiencing a corresponding rise in intracranial pressure (ICP). Measuring intracranial compliance can provide physicians a real-time predictive and quantitative value that helps determine the extent of damage to the brain and how well the patient is responding to therapy. 

Dr. Anders Korshøj, Associate Professor of Neurosurgery at Aarhus University Hospital, will lead the collaboration together with Naveed Ur Rehman, Assistant Professor in the Department of Electrical and Computer Engineering at Aarhus University, utilizing specialists from IRRAS, the hospital’s neurocritical care team, and data analytics experts from the Signal Processing and Machine Learning group at Aarhus University. 

“We are truly excited to engage in this multidisciplinary collaboration between IRRAS and our academic institutions,” said Dr. Korshøj. “At Aarhus University Hospital, we set the highest standards to bring innovative treatments like IRRAflow to patients and aim to advance treatments to the next level. This project is a strong example of our dedicated collective focus and close collaboration with leading experts in medical engineering to realize our ambition.”

Signal processing experts from the Department of Electrical and Computer Engineering at Aarhus University will play a key role in developing this novel technique to estimate brain compliance in real-time. Assistant Professor, Naveed ur Rehman, who heads the nonstationary signal processing group at ECE, will lead this specific activity.

“Our active participation in this interdisciplinary project is in line with our department’s mission to not only create new knowledge but to also shape these creations into workable solutions that better society,” said ur Rehman. “We strongly believe that this collaborative project will result in new ways to better treat neurotrauma patients, which is a goal that excites and motivates us as engineers.”

The Technology Transfer Office is a division of Aarhus University that provides resources and partnership opportunities to achieve commercialization of research projects. As part of this collaborative project, IRRAS shall retain an exclusive option to license the resulting technology. Eoin Galligan, Senior Business Development Manager, worked with Dr. Korshøj on the negotiations with IRRAS.

“TTO Business Development is very happy to complete this process and support this partnership with IRRAS,” said Galligan. “This project highlights how innovation partnerships can create ‘research impact,’ access corporate sponsorship for research, and bring next-generation technology into the clinic.”

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS). 

About Aarhus University and Aarhus University Hospital

Aarhus University Hospital belongs to the elite of university hospitals. Aarhus University Hospital develops and provides highly specialized medical treatment, research, and education at an international level. Aarhus University Hospital serves the citizens from across the central Denmark region in need of highly specialized treatment. For the last 14 years, Aarhus University Hospital has been appointed Denmark’s best hospital, and it currently ranks #32 on the Newsweek ranking of the world’s best hospitals.

Aarhus University (AU) is a dynamic, modern and highly international university. Since its founding in 1928, it has grown to become a leading public university with international impact and reach across the entire research spectrum. Out of over 17,000 universities worldwide, AU ranks among the top 100 universities in the world in several research areas and is considered among the top 25 universities in the European Union. AU stands out in particular in terms of research quality and the quality of degree programs. Regarding internationalization, AU is ranked in the top as well as no. 45 on THE’s ranking “Most International Universities in the World”.

The Department of Electrical and Computer Engineering at Aarhus University focus on research into hardware and software technologies that play a vital role in defining modern society, its digitalization and human behavior therein.

For more information, please contact:

USA
Will Martin
President and CEO
ir@irras.com 

Europe
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on October 22, 2021 at 08:30 (CET). 

Stockholm, October 15, 2021 – IRRAS, a global medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that it will be participating in-person at the Congress of Neurological Surgeons’ annual meeting (CNS 2021), in Austin, TX, on October 16-20, 2021, as well as the Neurocritical Care Society’s annual meeting (NCS 2021), in Chicago, IL, on October 26-29, 2021. In addition, at CNS 2021, clinical data regarding the use of its IRRAflow system in the treatment of intracerebral hemorrhage (ICH) and intraventricular hemorrhage (IVH) will be presented in a case series poster by Dr. Behnam Rezai Jahromi from Helsinki University Hospital.

Both the CNS and NCS annual meetings are well-respected global medical conferences that connect neurosurgeons, neurointensivists, and related healthcare professionals, and IRRAS will be well represented with its exhibitor booth, live product demonstrations, and the poster presentation. 

The poster presentation, titled “Active CSF Exchange is Effective for IVH Treatment – Active Removal of Intracerebral Hemorrhage,” will be available for review, both in-person and virtually, for registered participants of CNS 2021 beginning on Monday, October 18.

“Having the opportunity to participate in person at both the Congress of Neurological Surgeons and Neurocritical Care Society annual meetings is an important next step in our company’s emergence from the COVID-19 pandemic,” said Will Martin, President and Chief Executive Officer of IRRAS. “We are excited to connect with our customers in person, and we welcome all attendees to visit our IRRAS booth to learn more about our cutting-edge technologies.”

Conference attendees are encouraged to visit IRRAS’ booth #957 at CNS and booth #406 at NCS to learn more about IRRAflow®, the world’s first and only active fluid exchange system, as well as the Hummingbird Neuromonitoring product line.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS). 

For more information, please contact:

USA
Will Martin
President and CEO
ir@irras.com 

Europe
Sten Gustafsson
Director, Investor Relations
ir@irras.com 

The information was released for public disclosure, through the agency of the contact person above, on October 15, 2021 at 08:30 (CET). 

Stockholm, October 12, 2021 – IRRAS, a global medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that Aarhus University Hospital in Aarhus, Denmark, one of the world's leading medical institutions, has initiated commercial use of its IRRAflow system for a variety of neurocritical applications. 

The ACTIVE (Use of Active Fluid Exchange to Treat Intraventricular Hemorrhage (IVH)) clinical study will document the hospital’s use of the IRRAflow system and will compare it to the use of traditional passive ventricular drainage in EVD patients.  Dr. Anders Korshøj, Associate Professor of Neurosurgery from Aarhus University Hospital, will serve as the study’s Principal Investigator and will coordinate the study, with expected expansion to multiple sites across Denmark. 

"We are excited to finally begin treating patients with the IRRAflow system after lengthy delays due to COVID-19,” said Dr. Anders Korshøj.  “As we treat more patients, we look forward to presenting the data from the ACTIVE trial to show how the system's combination of automated irrigation and controlled drainage may reduce complications and improve long-term clinical outcomes.”

"Beginning commercial use of our IRRAflow system at Aarhus University signifies an important milestone for IRRAS," said Will Martin, President and Chief Executive Officer of IRRAS. "Our team has worked hard throughout the COVID-19 pandemic to train the Aarhus team, and we look forward to this hard work resulting in positive patient outcomes and compelling clinical data with the ACTIVE trial.”

Traditional treatment options for IVH patients generally utilize an external ventricular drainage (EVD) system, which is a passive approach that relies solely on gravity to facilitate drainage.  An EVD is currently the most common treatment option for intracranial bleeding or elevated intracranial pressure (ICP), but the technology’s shortcomings are well documented in scientific literature.  Complications such as catheter blockage, infections, and incomplete drainage occur regularly and negatively impact patient outcomes, lengthen required treatment time, and significantly increase the overall cost of care.  

The Department of Neurosurgery at Aarhus University Hospital is one of the leading neurosurgical departments in Denmark. The department is responsible for general neurosurgery and highly specialized neurosurgical procedures in Central Denmark Region. Moreover, the department is responsible for diagnostics, treatment, and care of patients with certain neurosurgical conditions in the entire country.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS). 

About Aarhus University and Aarhus University Hospital

Aarhus University Hospital belongs to the elite of university hospitals. Aarhus University Hospital develops and provides highly specialized medical treatment, research, and education at an international level. Aarhus University Hospital serves the citizens from across the central Denmark region in need of highly specialized treatment. For the last 14 years, Aarhus University Hospital has been appointed Denmark’s best hospital, and it currently ranks #32 on the Newsweek ranking of the world’s best hospitals.

Aarhus University (AU) is a dynamic, modern and highly international university. Since its founding in 1928, it has grown to become a leading public university with international impact and reach across the entire research spectrum. Out of over 17,000 universities worldwide, AU ranks among the top 100 universities in the world in several research areas and is considered among the top 25 universities in the European Union. AU stands out in particular in terms of research quality and the quality of degree programs. Regarding internationalization, AU is ranked in the top as well as no. 45 on THE’s ranking “Most International Universities in the World”.

For more information, please contact: 

USA
Will Martin
President and CEO
ir@irras.com 

Europe
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172 

The information was released for public disclosure, through the agency of the contact person above, on October 12, 2021 at 08:30 (CET).